Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine

Clalit Health Services

Status and phase: Terminated; Phase 2

Conditions: Perioperative Care; Parkinson Disease

Treatments: Drug: Amantadine

Study type: Interventional

Funder types: Other

Identifiers

NCT00600093

4332

Details and patient eligibility

About

The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.

Enrollment: 20 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with a diagnosis of Parkinson Disease refered for surgery at our institution.

Exclusion criteria

• Cardiac and neurosurgical procedures
• Inability to sign informed Consent
• allergy to Amantadine
• Congestive heart failure
• Arrythmia (including bradycardia below 55 bpm)
• renal failure (creatinin above 1.5)
• If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

A

Experimental group

Treatment:

Drug: Amantadine